Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 137,600 shares, a growth of 13.4% from the January 31st total of 121,300 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average trading volume of 154,300 shares, the short-interest ratio is presently 0.9 days.
Gain Therapeutics Trading Down 1.3 %
GANX opened at $4.66 on Wednesday. The company’s 50 day moving average is $4.02 and its 200-day moving average is $3.34. Gain Therapeutics has a 1-year low of $2.00 and a 1-year high of $6.19. The company has a current ratio of 2.30, a quick ratio of 2.30 and a debt-to-equity ratio of 0.06. The company has a market cap of $60.16 million, a P/E ratio of -2.57 and a beta of 0.47.
Wall Street Analyst Weigh In
Separately, HC Wainwright lowered their price objective on shares of Gain Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, December 4th.
Institutional Investors Weigh In On Gain Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Gain Therapeutics by 25.8% in the 4th quarter. Vanguard Group Inc. now owns 88,385 shares of the company’s stock valued at $289,000 after purchasing an additional 18,105 shares in the last quarter. Northern Trust Corp boosted its position in Gain Therapeutics by 227.7% during the 4th quarter. Northern Trust Corp now owns 43,513 shares of the company’s stock worth $142,000 after buying an additional 30,236 shares during the period. Royal Bank of Canada boosted its position in Gain Therapeutics by 947.6% during the 3rd quarter. Royal Bank of Canada now owns 210,000 shares of the company’s stock worth $689,000 after buying an additional 189,954 shares during the period. Renaissance Technologies LLC boosted its position in Gain Therapeutics by 23.0% during the 2nd quarter. Renaissance Technologies LLC now owns 47,600 shares of the company’s stock worth $213,000 after buying an additional 8,900 shares during the period. Finally, BlackRock Inc. boosted its position in Gain Therapeutics by 17.1% during the 2nd quarter. BlackRock Inc. now owns 29,024 shares of the company’s stock worth $130,000 after buying an additional 4,246 shares during the period. 9.99% of the stock is currently owned by institutional investors and hedge funds.
Gain Therapeutics Company Profile
Gain Therapeutics, Inc, a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.
Featured Articles
- Five stocks we like better than Gain Therapeutics
- Best Aerospace Stocks Investing
- Boeing Wants to Buy Its Supplier on Recent Drama, Here’s Why
- Investing in large cap stocks: Diving into big caps
- Cava Group Serves Up 60% Gain Amid Strong Post-IPO Buying
- Stock Market Upgrades: What Are They?
- Gitlab Goes on Sale: The AI Bubble Burst for This Stock
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.